Drug intelligence / Profile preview

LZ-RSV-001

Development stage: Preclinical
Lead developer: Zhifei Biological
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

LZ-RSV-001 is a recombinant protein vaccine candidate being developed by Beijing Luzhu Biotechnology (also known as Green Bamboo Biopharmaceutical) for the prevention of Respiratory Syncytial Virus (RSV) infection. The vaccine is designed to present specific RSV antigens to the host immune system to induce protective immunity, including the production of neutralizing antibodies and cellular immune responses. As of early 2024, the program is in the preclinical stage of development.

Targets

RSV F (Respiratory syncytial virus fusion protein)

Beyond the preview

Go deeper on LZ-RSV-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LZ-RSV-001.

Explore the full profile